1. Home >
  2. M&A >
  3. Divestiture >
  4. United States >
  5. Humanigen Acquires Savant Neglected Diseases - Benznidazole Program for the Treatment of Chagas Disease

M&A Deal Summary

Humanigen Acquires Savant Neglected Diseases - Benznidazole Program for the Treatment of Chagas Disease

On December 3, 2015, Humanigen acquired life science company Savant Neglected Diseases - Benznidazole Program for the Treatment of Chagas Disease from Savant Neglected Diseases for 3M USD

Acquisition Highlights
  • This is Humanigen’s 1st transaction in the Life Science sector.
  • This is Humanigen’s largest (disclosed) transaction.
  • This is Humanigen’s 1st transaction in the United States.

M&A Deal Summary
Date 2015-12-03
Target Savant Neglected Diseases - Benznidazole Program for the Treatment of Chagas Disease
Sector Life Science
Buyer(s) Humanigen
Sellers(s) Savant Neglected Diseases
Deal Type Divestiture
Deal Value 3M USD

Target

Savant Neglected Diseases - Benznidazole Program for the Treatment of Chagas Disease

United States
Savant Neglected Diseases - Benznidazole Program for the Treatment of Chagas Disease provides antitrypanosomal treatment for all cases of acute and congenital Chagas disease, reactivated infection, and chronic T. cruzi infection in individuals 18 years or younger.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Humanigen

Short Hills, California, United States
Category Company
Founded 2000
Sector Life Science
Employees11
DESCRIPTION

Humanigen is a bio-pharmaceutical company. Humanigen was founded in 2000 and is based in Short Hills, New Jersey.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
Country: United States M&A 1 of 1
Year: 2015 M&A 1 of 1
Size (of disclosed) 1 of 1

Seller(S) 1

SELLER

Savant Neglected Diseases

United States
Category Company
Sector Life Science
DESCRIPTION

Savant Neglected Diseases LLC is a privately-held specialty pharmaceutical company.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
Country: United States M&A 1 of 1
Year: 2015 M&A 1 of 1
Size (of disclosed) 1 of 1
Mergr

Solution for

Product

Company

Legal